Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
For the current fiscal year, the Company expects Group revenues in the range of
€760-800m (previously: € 840 - 880 m; 2024: € 797.0 m);
R&D expenditures are expected in a range of €40 - 50 m (unchanged; 2024: € 50.8 m);
Adjusted EBITDA is expected to reach €30-50m (unchanged; 2024: € 22.6 m).
The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing - a key pillar of Evotec's strategic repositioning - is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth.
- End of the ad hoc release -
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)151 1940 5058 (m), [email protected]
SOURCE: Evotec SE
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be available on Cerus' website and will be available approximately three hours after the call through August 26, 2025. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Yahoo
an hour ago
- Yahoo
Blockstream Expands in Europe With Acquisition of Swiss Crypto Firm Elysium Labs
Adam Back's Bitcoin development firm, Blockstream, has acquired Swiss blockchain startup Elysium Labs. The acquisition will see the creation of a European incubator entity, Blockstream CH SAGL, according to an emailed announcement shared with CoinDesk on Monday. The deal terms weren't disclosed by the firms. Blockstream is building momentum around its European ventures, following the inception of its Lugano Research Center, which is focused on product development of Bitcoin layer-2 networks Lightning and Liquid. The firm has not disclosed financial details of the acquisition. Blockstream CH SAGL will serve as a hub for Blockstream's European operations alongside its Turin, Italy-based research and development team and the Lugano Research Center, according to Monday's announcement. An early proponent of the cypherpunk movement, Blockstream CEO and co-founder Adam Back is a notable figure in Bitcoin lore. Back developed Hashcash in 1997 to combat email spam, which was a direct influence on Satoshi Nakamoto in creating Bitcoin's proof-of-work mechanism, and was cited as such in the original whitepaper. 'Bringing Elysium Lab into Blockstream strengthens our Swiss presence and amplifies our commitment to nurturing innovation across Europe,' Back said in Monday's announcement. Read More: Adam Back's Bitcoin Treasury Firm to Go Public with 30K BTC and $1.5B in Buying Power
Yahoo
an hour ago
- Yahoo
Stellantis Posts $2.7B First-Half Loss as Tariffs Hit Jeep Maker
Stellantis (STLA, Financials) reported a 2.3 billion ($2.7 billion) net loss for the first half of 2025, reversing a 5.6 billion profit from the same period a year ago, as tariffs, restructuring costs and weak shipments hit the automaker's bottom line. In preliminary results released Monday, the Jeep and Chrysler parent said it incurred 300 million ($349 million) in costs from early impacts of new U.S. tariffs. Revenue dropped 13% year over year to 74.3 billion from 85 billion. The company had suspended its full-year outlook in April citing tariff-related uncertainty. North American vehicle shipments in the second quarter fell 25% to 109,000 units, though U.S. retail sales were described as relatively flat, supported by a 13% gain from Jeep and Ram combined. Overall global sales declined 10% from a year earlier. This is the first earnings report under new CEO Antonio Filosa, who took over following the sudden exit of Carlos Tavares last December. Final results are due July 29. UBS analysts said Monday that Stellantis' free cash flow is likely to remain negative in 2025, as the second half is unlikely to offset the first-half cash burn. Shares were little changed in premarket trading and are down nearly 30% year to date. This article first appeared on GuruFocus.
